Nuvectis Pharma Announces New ATM Offering Program with Jefferies

What Happened
Nuvectis Pharma, Inc. announced on August 21, 2026 that it entered into an Open Market Sale Agreement with Jefferies LLC to act as sales agent for an at-the-market (ATM) offering of its common stock. The company filed a new Form S-3 registration statement on August 21, 2026 registering up to $200 million of securities and expects to file a prospectus supplement relating to the Sale Agreement. The Sale Agreement allows the company to sell shares from time to time in “at the market” transactions under Rule 415(a)(4).

Key Details

• Agreement date: August 21, 2026; Registration Statement (Form S-3) filed August 21, 2026 registering $200 million in securities.
• Jefferies acts as sales agent and is not required to sell any specified amount; sales occur on mutually agreed terms and are subject to applicable law.
• Jefferies’ maximum cash compensation: up to 3.0% of gross proceeds from ATM shares sold.
• Nuvectis agreed to reimburse certain expenses and provide customary indemnification to Jefferies; the company terminated its prior ATM program on July 20, 2026.

Why It Matters
This filing gives Nuvectis a flexible way to raise capital over time by selling shares into the market rather than through a single block offering. The actual dilutive impact and cash raised depend on how many shares are sold and at what prices; there is no guarantee any shares will be sold. Investors should note the added selling arrangement with Jefferies (including up to 3.0% fees) and the formal wind-down of the prior ATM program.